This correlated with CSF levels of Aβ1–42, total Tau, and phosphorylated Tau (T181), which are a sign of cognitive decline or dementia in some PD patients [59]: Mut1 presented with lower levels of Aβ1–42 and higher levels of total and phosphorylated Tau, while levels of these biomarkers in Mut2 were detected in the normal range according to lab cutoffs (Aβ1–42 < 599 pg/mL, total Tau > 404 pg/mL, and phosphorylated Tau > 56.5 pg/mL). The gene discussed is MAPT; the disease is Parkinson disease.